Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.

Publication date: Aug 01, 2024

Novel mRNA-based vaccines have been proven to be powerful tools in combating the global pandemic caused by SARS-CoV-2 protecting individuals, especially the immunocompromised, from COVID-19. Still, it remains largely unknown how solid organ transplant and different immunosuppressive medications affect development of vaccine-induced immunity. In this work, we monitored humoral and cellular memory responses after mRNA SARS-CoV-2 two-doses and booster doses vaccination in cystic fibrosis lung transplanted patients (CFT) and compared them with both cystic fibrosis patients without lung transplant (CF) and with kidney transplant recipients (KT). In particular, we investigated the effects of immunosuppressive regimens on immune memory to SARS-CoV-2 after mRNA SARS-CoV-2 vaccine in transplanted patients. Our results showed that immunocompromised transplanted patients displayed a weak cellular and humoral memory to SARS-CoV-2 mRNA vaccination. In addition, obtained data clearly demonstrate that immunosuppressive therapy regimen including antimetabolites, further reduces patients’ ability to respond to vaccination at both humoral and cell-mediated level. Notably, patient treated with antimetabolites showed a lower humoral and cellular response also after a booster dose vaccination. These results, even if obtained on a small patient’s cohort, question whether immunocompromised patients need interventions to improve vaccine SARS-CoV-2 mRNA vaccine response such as additional jab or modulation of immunosuppressive therapy.

Concepts Keywords
Global Adult
Immunocompromised Antibodies, Viral
Kidney Antibodies, Viral
Organ Antimetabolites
Unknown COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Cystic Fibrosis
Cystic fibrosis
Female
Humans
Immunity, Cellular
Immunity, Humoral
Immunization, Secondary
Immunocompromised Host
Immunologic Memory
Immunosuppressive Agents
Immunosuppressive Agents
Kidney Transplantation
Lung Transplantation
Male
Middle Aged
mRNA vaccine
Organ Transplantation
SARS-CoV-2
SARS-CoV-2
Solid organ transplant
T cell response
Transplant Recipients
Vaccination

Semantics

Type Source Name
disease IDO humoral immune response
disease VO vaccination
disease MESH COVID-19
disease VO vaccine
disease MESH cystic fibrosis
disease IDO cell
disease VO dose
disease MESH immunocompromised patients
disease VO immunization
disease VO organ

Original Article

(Visited 2 times, 1 visits today)